PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER

摘要

The present invention relates to Pyrazolo [1,5-a]pyrimidine compounds of formula III usefu as protein kinase inhibitors, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases such as, for example, cancer, inflammation, arthritis, viral diseases, neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, and fungal diseases (Formula III), wherein : R is an aryl substituted with one or more heteroaryl; R<SUP>2</SUP> is selected from the group consisting of R<SUP>9</SUP>, alkyl, alkynyl, alkynylalkyl, cycloalkyl, -CF<SUB>3</SUB>, -C(O<SUB>2</SUB>)R<SUP>6</SUP>, aryl, arylalkyl, heteroarylalkyl, heterocyclyl, alkyl substituted with 1-6 R<SUP>9</SUP> groups which groups can be the same or different with each R<SUP>9</SUP> being independently selected, aryl substituted with 1-3 aryl or heteroaryl groups which can be the same or different and are independently selected from phenyl, pyridyl, thiophenyl, furanyl and thiazolo groups, (a), (b), (c) and (d), and heteroaryl substituted with 0-3 aryl or heteroaryl groups which can be the same or different and are independently selected from alkyl, phenyl, pyridyl, thiophenyl, furapyl and thiazolo groups; R<SUP>3</SUP> is selected from the group consisting of H, halogen, -NR<SUP>5</SUP>R<SUP>6</SUP>, -C(O)NR<SUP>5</SUP>R<SUP>6</SUP>, alkyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl, etc; R<SUP>4</SUP> is H halo or alkyl.